Bevacizumab

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instanceOf gptkb:monoclonal_antibody
anti-angiogenic drug
gptkbp:administeredBy gptkb:physician
gptkbp:approvedBy gptkb:FDA
gptkb:EMA
2004
gptkbp:ATCCode L01XC07
gptkbp:biosimilar gptkb:Alymsys
gptkb:Mvasi
gptkb:Zirabev
Aybintio
gptkbp:brand gptkb:Avastin
gptkbp:CASNumber 216974-75-3
gptkbp:chemicalFormula C6638H10160N1720O2104S44
gptkbp:contraindication uncontrolled hypertension
hypersensitivity to bevacizumab
recent surgery
gptkbp:cost high
gptkbp:developedBy gptkb:Genentech
gptkbp:eliminationHalfLife 20 days
https://www.w3.org/2000/01/rdf-schema#label Bevacizumab
gptkbp:KEGGID D04139
gptkbp:legalStatus prescription only
expired in US
gptkbp:marketedAs gptkb:Roche
gptkbp:mechanismOfAction inhibits VEGF-A
gptkbp:MedlinePlusID a607001
gptkbp:molecularWeight 149 kDa
gptkbp:pregnancyCategory D (US)
gptkbp:PubChem_CID DB00112
24859646
CHEMBL1201588
gptkbp:routeOfAdministration intravenous
gptkbp:sideEffect bleeding
hypertension
proteinuria
gastrointestinal perforation
impaired wound healing
gptkbp:target gptkb:VEGF-A
gptkbp:type humanized monoclonal antibody
gptkbp:UNII 82S8T18449
gptkbp:usedFor gptkb:non-small_cell_lung_cancer
gptkb:cancer
gptkb:fallopian_tube_cancer
gptkb:glioblastoma
colorectal cancer
age-related macular degeneration
renal cell carcinoma
peritoneal cancer
gptkbp:WHOModelListOfEssentialMedicines included
gptkbp:bfsParent gptkb:Non-Small_Cell_Lung_Cancer
gptkbp:bfsLayer 6